Physician profile
Robert A Sweet
NPI 1548262223
$873.69
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $233 · 2022: $64.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $187.88 | 2019-2020 | |
| Amarin Pharma, INC. | $170.70 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $136.13 | 2019 | |
| Novo Nordisk INC | $111.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $80.42 | 2019 | |
| Straumann USA LLC | $64.10 | 2022 | |
| Lilly USA, LLC | $62.16 | 2019-2020 | |
| Pfizer INC. | $24.48 | 2019 | |
| Merck Sharp & Dohme LLC | $24.42 | 2019 | |
| Adlon Therapeutics L.P. | $11.91 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sweet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.